{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T02:37:07Z","timestamp":1783996627087,"version":"3.55.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Res Notes"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Cutaneous Crohn\u2019s Disease is a notoriously difficult condition to treat and causes significant morbidity, impacting heavily on quality of life. This is the first study in adults examining the effect of topical tacrolimus on the different cutaneous manifestations of Crohn\u2019s Disease.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This open label observational study of 20 patients with heterogeneous forms of cutaneous Crohn\u2019s disease used topical tacrolimus 0.1% ointment once daily to affected areas for 12 weeks with a maximal total dose of 90g. Therapy was stopped at 12 weeks to assess whether the condition relapsed. Thereafter relapsing patients optionally continued an open label extension of topical tacrolimus therapy and were observed for a total of 12 months.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Of seventeen patients completing the twelve-week study, fifteen improved using a specifically designed physicians\u2019 global severity scale. One patient cleared, four showed a pronounced improvement (51-75%) and ten demonstrated a mild (1-25%) or moderate improvement (25-50%) in twelve weeks. Over twelve months eleven patients remained in the study, nine of which improved, one cleared and one showed no change. Perineal disease responded better with two out of twelve clearing, four showing pronounced benefit and four mild to moderate improvement. Long-term application of 0.1% tacrolimus applied to broken skin and mucosa was safe and serum levels of tacrolimus were undetectable in all subjects throughout the study.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>0.1% tacrolimus ointment was safe and effective in treating cutaneous manifestations of Crohn\u2019s disease, particularly perineal disease and pyoderma gangrenosum, yet it seldom cleared the condition.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Clinical trial registration<\/jats:title>\n            <jats:p>ClinicalTrials.gov Protocol Registration System ID: 33000332<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1756-0500-6-19","type":"journal-article","created":{"date-parts":[[2013,1,18]],"date-time":"2013-01-18T11:14:15Z","timestamp":1358507655000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Topical tacrolimus 0.1% ointment for treatment of cutaneous Crohn\u2019s Disease"],"prefix":"10.1186","volume":"6","author":[{"given":"Shantini A","family":"Rice","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pick N","family":"Woo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emad","family":"El-Omar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald A","family":"Keenan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony D","family":"Ormerod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,1,18]]},"reference":[{"issue":"1","key":"2119_CR1","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1053\/jpsu.2002.29434","volume":"37","author":"AJ Watson","year":"2002","unstructured":"Watson AJ, Johnston AT, Barker PM, Youngson GG, Bisset WM, Mahomed AA: The presentation and management of juvenile-onset chronic inflammatory bowel disease in Northeastern Scotland. J Pediatr Surg. 2002, 37 (1): 83-86. 10.1053\/jpsu.2002.29434.","journal-title":"J Pediatr Surg"},{"issue":"5","key":"2119_CR2","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1002\/ibd.20352","volume":"14","author":"M Economou","year":"2008","unstructured":"Economou M, Pappas G: New global map of Crohn\u2019s disease: Genetic, environmental, and socioeconomic correlations. Inflamm Bowel Dis. 2008, 14 (5): 709-720. 10.1002\/ibd.20352.","journal-title":"Inflamm Bowel Dis"},{"issue":"4","key":"2119_CR3","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1053\/j.gastro.2004.06.024","volume":"127","author":"EL Armitage","year":"2004","unstructured":"Armitage EL, Aldhous MC, Anderson N, et al: Incidence of juvenile-onset Crohn\u2019s disease in Scotland: association with northern latitude and affluence. Gastroenterology. 2004, 127 (4): 1051-1057. 10.1053\/j.gastro.2004.06.024.","journal-title":"Gastroenterology"},{"issue":"6","key":"2119_CR4","first-page":"365","volume":"57","author":"RM Bland","year":"1999","unstructured":"Bland RM, Evans TJ, Raine P, Weaver LT: Inflammatory bowel disease in Scottish children. Health Bull (Edinb). 1999, 57 (6): 365-373.","journal-title":"Health Bull (Edinb)"},{"issue":"2","key":"2119_CR5","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/0016-5085(92)90826-K","volume":"103","author":"J Kyle","year":"1992","unstructured":"Kyle J: Crohn\u2019s disease in the northeastern and northern Isles of Scotland: an epidemiological review. Gastroenterology. 1992, 103 (2): 392-399.","journal-title":"Gastroenterology"},{"issue":"1","key":"2119_CR6","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1046\/j.1572-0241.2003.04010.x","volume":"99","author":"GR Lichtenstein","year":"2004","unstructured":"Lichtenstein GR, Yan S, Bala M, Hanauer S: Remission in patients with Crohn\u2019s disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am J Gastroenterol. 2004, 99 (1): 91-96. 10.1046\/j.1572-0241.2003.04010.x.","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"2119_CR7","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1111\/j.1572-0241.2001.04681.x","volume":"96","author":"F Blondel-Kucharski","year":"2001","unstructured":"Blondel-Kucharski F, Chircop C, Marquis P, et al: Health-related quality of life in Crohn\u2019s disease: a prospective longitudinal study in 231 patients. Am J Gastroenterol. 2001, 96 (10): 2915-2920. 10.1111\/j.1572-0241.2001.04681.x.","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"2119_CR8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000083870","volume":"71","author":"P Juillerat","year":"2005","unstructured":"Juillerat P, Mottet C, Froehlich F, et al: Extraintestinal manifestations of Crohn\u2019s disease. Digestion. 2005, 71 (1): 31-36. 10.1159\/000083870.","journal-title":"Digestion"},{"issue":"Suppl 4","key":"2119_CR9","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/j.1365-2036.2004.02055.x","volume":"20","author":"F Tavarela Veloso","year":"2004","unstructured":"Tavarela Veloso F: Review article: skin complications associated with inflammatory bowel disease. Aliment Pharmacol Ther. 2004, 20 (Suppl 4): 50-53.","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"2119_CR10","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/S0190-9622(81)70130-0","volume":"5","author":"W Burgdorf","year":"1981","unstructured":"Burgdorf W: Cutaneous manifestations of Crohn\u2019s disease. J Am Acad Dermatol. 1981, 5 (6): 689-695. 10.1016\/S0190-9622(81)70130-0.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"2119_CR11","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1111\/j.1463-1318.2004.00607.x","volume":"6","author":"M Khurrum Baig","year":"2004","unstructured":"Khurrum Baig M, Marquez H, Nogueras JJ, Weiss EG, Wexner SD: Topical tacrolimus (FK506) in the treatment of recalcitrant parastomal pyoderma gangrenosum associated with Crohn\u2019s disease: report of two cases. Colorectal Dis. 2004, 6 (4): 250-253. 10.1111\/j.1463-1318.2004.00607.x.","journal-title":"Colorectal Dis"},{"issue":"9","key":"2119_CR12","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1111\/j.1468-3083.2008.02741.x","volume":"22","author":"I Palamaras","year":"2008","unstructured":"Palamaras I, El-Jabbour J, Pietropaolo N, et al: Metastatic Crohn\u2019s disease: a review. J Eur Acad Dermatol Venereol. 2008, 22 (9): 1033-1043. 10.1111\/j.1468-3083.2008.02741.x.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"2119_CR13","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1016\/S1567-5769(01)00059-5","volume":"1","author":"S Sakuma","year":"2001","unstructured":"Sakuma S, Higashi Y, Sato N, et al: Tacrolimus suppressed the production of cytokines involved in atopic dermatitis by direct stimulation of human PBMC system. (Comparison with steroids). Int Immunopharmacol. 2001, 1 (6): 1219-1226. 10.1016\/S1567-5769(01)00059-5.","journal-title":"Int Immunopharmacol"},{"issue":"9","key":"2119_CR14","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.7164\/antibiotics.40.1256","volume":"40","author":"T Kino","year":"1987","unstructured":"Kino T, Hatanaka H, Miyata S, et al: FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot (Tokyo). 1987, 40 (9): 1256-1265. 10.7164\/antibiotics.40.1256.","journal-title":"J Antibiot (Tokyo)"},{"issue":"4","key":"2119_CR15","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1111\/j.1365-2133.2008.08747.x","volume":"159","author":"S Reitamo","year":"2008","unstructured":"Reitamo S, Rustin M, Harper J, et al: A 4-year follow-up study of atopic dermatitis therapy with 0.1% tacrolimus ointment in children and adult patients. Br J Dermatol. 2008, 159 (4): 942-951. 10.1111\/j.1365-2133.2008.08747.x.","journal-title":"Br J Dermatol"},{"issue":"1","key":"2119_CR16","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1001\/archderm.141.1.43","volume":"141","author":"CL Carroll","year":"2005","unstructured":"Carroll CL, Clarke J, Camacho F, Balkrishnan R, Feldman SR: Topical tacrolimus ointment combined with 6% salicylic acid gel for plaque psoriasis treatment. Arch Dermatol. 2005, 141 (1): 43-46. 10.1001\/archderm.141.1.43.","journal-title":"Arch Dermatol"},{"issue":"10","key":"2119_CR17","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1517\/14656566.5.10.2127","volume":"5","author":"CL Carroll","year":"2004","unstructured":"Carroll CL, Fleischer AB: Tacrolimus ointment: the treatment of atopic dermatitis and other inflammatory cutaneous disease. Expert Opin Pharmacother. 2004, 5 (10): 2127-2137. 10.1517\/14656566.5.10.2127.","journal-title":"Expert Opin Pharmacother"},{"issue":"4","key":"2119_CR18","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1111\/j.1468-3083.2008.03056.x","volume":"23","author":"A Katsarou","year":"2009","unstructured":"Katsarou A, Armenaka M, Vosynioti V, Lagogianni E, Kalogeromitros D, Katsambas A: Tacrolimus ointment 0.1% in the treatment of allergic contact eyelid dermatitis. J Eur Acad Dermatol Venereol. 2009, 23 (4): 382-387. 10.1111\/j.1468-3083.2008.03056.x.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"2119_CR19","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1093\/rheumatology\/39.1.105","volume":"39","author":"H Schuppe","year":"2000","unstructured":"Schuppe H, Richter-Hintz D, Stierle HE, Homey B, Ruzicka T, Lehmann P: Topical tacrolimus for recalcitrant leg ulcer in rheumatoid arthritis. Rheumatology (Oxford). 2000, 39 (1): 105-106. 10.1093\/rheumatology\/39.1.105.","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"2119_CR20","first-page":"665","volume":"16","author":"S Elad","year":"2003","unstructured":"Elad S, Or R, Resnick I, Shapira MY: Topical tacrolimus\u2013a novel treatment alternative for cutaneous chronic graft-versus-host disease. Transpl Int. 2003, 16 (9): 665-670.","journal-title":"Transpl Int"},{"issue":"9","key":"2119_CR21","first-page":"1202","volume":"137","author":"CJ Choi","year":"2001","unstructured":"Choi CJ, Nghiem P: Tacrolimus ointment in the treatment of chronic cutaneous graft-vs-host disease: a case series of 18 patients. Arch Dermatol. 2001, 137 (9): 1202-1206.","journal-title":"Arch Dermatol"},{"issue":"5","key":"2119_CR22","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1080\/09546630410018247","volume":"15","author":"MA Thomson","year":"2004","unstructured":"Thomson MA, Hamburger J, Stewart DG, Lewis HM: Treatment of erosive oral lichen planus with topical tacrolimus. J Dermatolog Treat. 2004, 15 (5): 308-314. 10.1080\/09546630410018247.","journal-title":"J Dermatolog Treat"},{"issue":"4","key":"2119_CR23","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1067\/mjd.2002.126275","volume":"47","author":"L Morrison","year":"2002","unstructured":"Morrison L, Kratochvil FJ, Gorman A: An open trial of topical tacrolimus for erosive oral lichen planus. J Am Acad Dermatol. 2002, 47 (4): 617-620. 10.1067\/mjd.2002.126275.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"2119_CR24","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1136\/gut.47.3.436","volume":"47","author":"DH Casson","year":"2000","unstructured":"Casson DH, Eltumi M, Tomlin S, Walker-Smith JA, Murch SH: Topical tacrolimus may be effective in the treatment of oral and perineal Crohn's disease. Gut. 2000, 47 (3): 436-440. 10.1136\/gut.47.3.436.","journal-title":"Gut"},{"issue":"3","key":"2119_CR25","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/ibd.20073","volume":"13","author":"AL Hart","year":"2007","unstructured":"Hart AL, Plamondon S, Kamm MA: Topical tacrolimus in the treatment of perianal Crohn\u2019s disease: exploratory randomized controlled trial. Inflamm Bowel Dis. 2007, 13 (3): 245-253. 10.1002\/ibd.20073.","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"2119_CR26","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.anpedi.2009.03.005","volume":"70","author":"VM Navas Lopez","year":"2009","unstructured":"Navas Lopez VM, Blasco Alonso J, Sierra Salinas C, Barco Galvez A, Vicioso Recio MI: [Safety and efficacy of oral tacrolimus in the treatment of paediatric inflammatory bowel disease]. Anales de Pediatria. 2009, 70 (6): 519-525. 10.1016\/j.anpedi.2009.03.005.","journal-title":"Anales de Pediatria"},{"issue":"10","key":"2119_CR27","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1007\/s00535-008-2229-y","volume":"43","author":"H Tamaki","year":"2008","unstructured":"Tamaki H, Nakase H, Matsuura M, et al: The effect of tacrolimus (FK-506) on Japanese patients with refractory Crohn\u2019s disease. J Gastroenterol. 2008, 43 (10): 774-779. 10.1007\/s00535-008-2229-y.","journal-title":"J Gastroenterol"},{"issue":"1","key":"2119_CR28","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/ibd.20263","volume":"14","author":"A Benson","year":"2008","unstructured":"Benson A, Barrett T, Sparberg M, et al: Efficacy and safety of tacrolimus in refractory ulcerative colitis and Crohn\u2019s disease: a single-center experience. Inflamm Bowel Dis. 2008, 14 (1): 7-12. 10.1002\/ibd.20263.","journal-title":"Inflamm Bowel Dis"},{"issue":"10","key":"2119_CR29","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1007\/s10620-006-9209-y","volume":"51","author":"Y Gonzalez-Lama","year":"2006","unstructured":"Gonzalez-Lama Y, Gisbert JP, Mate J, Gonzalez-Lama Y, Gisbert JP, Mate J: The role of tacrolimus in inflammatory bowel disease: a systematic review. Digest Dis Sci. 2006, 51 (10): 1833-1840. 10.1007\/s10620-006-9209-y.","journal-title":"Digest Dis Sci"},{"issue":"3","key":"2119_CR30","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1046\/j.1365-2036.2001.00938.x","volume":"15","author":"E Ierardi","year":"2001","unstructured":"Ierardi E, Principi M, Francavilla R, et al: Oral tacrolimus long-term therapy in patients with Crohn\u2019s disease and steroid resistance. Aliment Pharmacol Ther. 2001, 15 (3): 371-377. 10.1046\/j.1365-2036.2001.00938.x.","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"2119_CR31","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/S0016-5085(03)00877-1","volume":"125","author":"WJ Sandborn","year":"2003","unstructured":"Sandborn WJ, Present DH, Isaacs KL, et al: Tacrolimus for the treatment of fistulas in patients with Crohn\u2019s disease: a randomized, placebo-controlled trial. Gastroenterology. 2003, 125 (2): 380-388. 10.1016\/S0016-5085(03)00877-1.","journal-title":"Gastroenterology"},{"issue":"1","key":"2119_CR32","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/00054725-200501000-00002","volume":"11","author":"Y Gonzalez-Lama","year":"2005","unstructured":"Gonzalez-Lama Y, Abreu L, Vera MI, et al: Long-term oral tacrolimus therapy in refractory to infliximab fistulizing Crohn\u2019s disease: a pilot study. Inflamm Bowel Dis. 2005, 11 (1): 8-15. 10.1097\/00054725-200501000-00002.","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"2119_CR33","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1097\/00005176-200102000-00022","volume":"32","author":"RK Russell","year":"2001","unstructured":"Russell RK, Richardson N, Wilson DC: Systemic absorption with complications during topical tacrolimus treatment for orofacial Crohn disease. J Pediatr Gastroenterol Nutr. 2001, 32 (2): 207-208. 10.1097\/00005176-200102000-00022.","journal-title":"J Pediatr Gastroenterol Nutr"}],"container-title":["BMC Research Notes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1756-0500-6-19.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T22:46:06Z","timestamp":1630536366000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcresnotes.biomedcentral.com\/articles\/10.1186\/1756-0500-6-19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,18]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["2119"],"URL":"https:\/\/doi.org\/10.1186\/1756-0500-6-19","relation":{},"ISSN":["1756-0500"],"issn-type":[{"value":"1756-0500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,18]]},"assertion":[{"value":"13 November 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2012","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"19"}}